Government · 2 deals
Every published round National Institutes of Health took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Neurizon Therapeutics Limited | Grant | 9 Sep 2026 | - | Lead | Biotech Dispatch | |
| Ellume Health | Grant | Oct 2020 | US$30m ($42.6m) | Lead | Startup Daily, SmartCompany |
Companies National Institutes of Health has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Ellume Health | Oct 2020, Grant | 1 | 1 | |
| Neurizon Therapeutics Limited | 9 Sep 2026, Grant | 1 | 1 |
Fund closes reported for National Institutes of Health, as distinct from the investments it has made.
Companies National Institutes of Health has backed that another company then bought. An exit for the holding, not a deal National Institutes of Health did.
Stories naming National Institutes of Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Neurizon Therapeutics appoints Chris Bremer as CEO while interim executive chairman Sergio Duchini becomes non-executive chairman, with the company's ALS drug awaiting Phase 2/3 trial results in 2027.
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.
Vaxxas, a Brisbane biotech, has taken a worldwide licence from the US NIH to an RSV antigen candidate, aiming to advance it toward a Phase I study; another trial runs with BARDA funding.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Brisbane diagnostics company Ellume signed a US government contract worth US$231.8 million to supply Covid-19 home tests and build a US factory, alongside earlier grants from the NIH and Queensland government.
Also SmartCompany·SmartCompany·Startup Daily·@AuManufacturing
Brisbane diagnostics company Ellume wins US emergency authorisation for its COVID-19 home test, backed by an earlier NIH grant and a mid-2020 private raise as it scales production.
Also Startup Daily
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.